Side Effects After Direct-acting Antiviral Treatment

Side Effects After Direct-acting Antiviral Treatment in Patients With Chronic Hepatitis C. The EFINO-C Study.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03346941

Acronym

EFINO-C

Enrollment

Registered

2017-11-20

Start date

2016-05-01

Completion date

2017-10-31

Last updated

2017-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis c

Brief summary

The objective of this study was to assess the incidence of side effects after direct-acting antiviral therapy in patients with chronic hepatitis C virus infection.

Detailed description

Direct-acting antiviral (DAA)-based treatments are today very effective The objective of this study was to assess the incidence of side effects after DAA therapy in patients with chronic hepatitis C virus infection.

Interventions

DRUGDAA treatment

Direct-acting antiviral-based treatment

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* 18 years of age or older * Hepatitis C virus infection * Treatment by direct-acting antiviral combination

Exclusion criteria

* HIV coinfection

Design outcomes

Primary

Measure	Time frame	Description
Incidence of side effects	Within treatment duration, i.e. 8, 12 or 24 weeks after treatment initiation	Incidence of side effects occurring during treatment duration. Treatment duration may be of 8 weeks, 12 weeks or 24 weeks depending on treatment combination.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026